Institution
Department of Biotechnology
Government•New Delhi, India•
About: Department of Biotechnology is a government organization based out in New Delhi, India. It is known for research contribution in the topics: Population & Silver nanoparticle. The organization has 4800 authors who have published 5033 publications receiving 82022 citations.
Topics: Population, Silver nanoparticle, DPPH, Gene, Oxidative stress
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Phytoremediation studies indicated that treatment of H. annuus with the isolate MG had the maximum metal-accumulation in shoots and a significant increase in the soil extracellular enzyme-activities was observed in myco-phytoremediated soils.
93 citations
••
TL;DR: It is suggested that strategically chosen food components might be highly effective in the prevention of HFD‐induced alterations and may further be developed as functional foods.
92 citations
••
TL;DR: Novel molecules that are HDAC isoform specific, superior to first generation HDAC inhibitors like SAHA (Suberoylanilide Hydroxamic Acid) and TSA (Trichostatin A) and can be modified structurally to reduce toxic side effects and increase specificity are reviewed.
Abstract: Malignant growth of cells is a condition characterized by unchecked cellular proliferation, genetic instability and epigenetic dysregulation. Up-regulated HDAC (Histone Deacetylase) enzyme activity is associated with a closed chromatin assembly and subsequent gene repression, forming a characteristic feature of malignantly transformed cells. Novel therapeutics are now targeting the zinc containing HDAC enzymes for treating various types of cancers. Recently, a spate of drugs acting via HDAC inhibition have been undergoing clinical trials and several patents present exciting molecules like PCI-24781 (Abexinostat), ITF- 2357 (Givinostat); MS-275 (Entinostat), MGCD 0103 (Mocetinostat), LBH-589 (Panobinostat), FK228 (Romidepsin), PXD-101 (Belinostat) and Valproic Acid to be used as alternatives or adjuvants to traditional chemotherapeutics. However, only three HDAC inhibitors have acquired FDA approval till date. Recently, PXD-101 obtained FDA approval for the treatment of Refractory or Relapsed Peripheral T cell lymphoma. The current article reviews patents that have introduced novel molecules that are HDAC isoform specific, superior to first generation HDAC inhibitors like SAHA (Suberoylanilide Hydroxamic Acid) and TSA (Trichostatin A) and can be modified structurally to reduce toxic side effects and increase specificity. These molecules can combine the best characteristics of an ideal HDAC inhibiting drug either as monotherapy or in combinatorial therapy for cancer treatment thus, indicating promise to be included in the next generation of target specific HDAC inhibiting drugs.
92 citations
••
TL;DR: It is proposed that the bridging coordination of the C-terminal Fe-S cluster may be ideal for its facile assembly, labile binding, and efficient transfer to target Fe- S apoproteins, a step facilitated by the cytosolic iron-sulfur (Fe-S) protein assembly proteins Nar1 and Cia1 in vivo.
92 citations
••
TL;DR: Structure and regulation/deregulation of mTOR provides a greater insight into the action mechanism of PI3K/Akt/mTOR pathway besides targeted therapies for breast cancer and the precise role of m TOR.
Abstract: Background: The most recurrent and considered second most frequent cause of cancer-related deaths worldwide in women is the breast cancer. The key to diagnosis is early prediction and a curable stage but still treatment remains a great clinical challenge. Origin of the Problem: A number of studies have been carried out for the treatment of breast cancer which includes the targeted therapies and increased survival rates in women. Essential PI3K/mTOR signaling pathway activation has been observed in most breast cancers. The cell growth and tumor development in such cases involve phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) complex intracellular pathway. Hypothesis: Through preclinical and clinical trials, it has been observed that there are a number of other inhibitors of PI3K/Akt/mTOR pathway, which either alone or in combination with cytotoxic agents can be used for endocrine therapies. Conclusion: Structure and regulation/deregulation of mTOR provides a greater insight into the action mechanism. Also, through this review, one could easily scan first and second generation inhibitors for PI3K/Akt/mTOR pathway besides targeted therapies for breast cancer and the precise role of mTOR.
92 citations
Authors
Showing all 4812 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ashok Pandey | 96 | 796 | 43038 |
Klaus Becker | 79 | 320 | 27494 |
Bansi D. Malhotra | 75 | 375 | 19419 |
Ashwani Kumar | 66 | 703 | 18099 |
Sanjay K. Banerjee | 62 | 798 | 30044 |
M. Michael Gromiha | 56 | 352 | 10617 |
Swaran J.S. Flora | 55 | 267 | 11434 |
Mallappa Kumara Swamy | 54 | 864 | 14508 |
Pulok K. Mukherjee | 54 | 296 | 10873 |
Mukesh Doble | 51 | 364 | 9826 |
Jaya Narayan Sahu | 49 | 157 | 9569 |
Pradeep Das | 49 | 426 | 10118 |
Jon R. Lorsch | 48 | 117 | 7661 |
Rakesh Tuli | 47 | 165 | 7497 |
Amit K. Goyal | 47 | 157 | 5749 |